FY2025 · ended Dec 31, 2025 · Revenue $77.36M, -3.1% YoY · Filed Mar 4, 2026
Sight Sciences, Inc. (SGHT) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $77.4 million and a net loss of $38.4 million. Free cash flow was -$29.9 million. As of Sep 30, 2026 it held $77.4 million in cash and investments and $48.2 million in total debt.
Revenue (TTM)
$88.39M
+16.2% vs year-ago TTM
Net income (TTM)
$-28.40M
+38.4% vs year-ago TTM
Operating cash flow (TTM)
$-16.92M
+46.0% vs year-ago TTM
Free cash flow (TTM)
$-16.93M
+46.8% vs year-ago TTM
EPS (TTM)
$-0.52
+41.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
54.01M
+5.2% vs prior year
Net cash
$29.23M
as of Sep 30, 2026
Operating margin
-29.5%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- SGHT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1531177
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M |
| Operating income | -$37.1M | -$50.5M | -$57.3M | -$84.0M | -$51.5M |
| Net income | -$38.4M | -$51.5M | -$55.5M | -$86.2M | -$63.0M |
| Diluted EPS | -$0.74 | -$1.03 | -$1.14 | -$1.80 | — |
| Operating cash flow | -$29.7M | -$22.4M | -$47.2M | -$76.0M | -$52.5M |
| Free cash flow | -$29.9M | -$22.7M | -$48.0M | -$76.9M | -$53.4M |
| Total assets | $115.3M | $142.8M | $166.7M | $213.1M | $280.2M |
| Total liabilities | $51.4M | $55.3M | $46.4M | $53.0M | $48.1M |
| Stockholders' equity | $63.9M | $87.5M | $120.2M | $160.1M | $232.1M |
| Cash and investments | $92.0M | $120.4M | $138.1M | $185.0M | $260.7M |
| Total debt | $40.8M | $40.4M | $35.4M | $35.0M | $34.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
All 507 Sight Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.